Dashboard
1
The company has declared Positive results for the last 4 consecutive quarters
- NET PROFIT(HY) At CNY 198.85 MM has Grown at 226.81%
- NET SALES(9M) At CNY 2,490.01 MM has Grown at 20.77%
- DEBT-EQUITY RATIO (HY) Lowest at -3.6 %
2
With ROE of 11.00%, it has a attractive valuation with a 0.95 Price to Book Value
3
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,051 Million (Mid Cap)
9.00
NA
0.54%
-0.10
12.52%
1.09
Revenue and Profits:
Net Sales:
920 Million
(Quarterly Results - Sep 2025)
Net Profit:
152 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.76%
0%
-4.76%
6 Months
15.91%
0%
15.91%
1 Year
20.22%
0%
20.22%
2 Years
66.92%
0%
66.92%
3 Years
-11.86%
0%
-11.86%
4 Years
-18.94%
0%
-18.94%
5 Years
-41.43%
0%
-41.43%
Allmed Medical Products Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.54%
EBIT Growth (5y)
-14.87%
EBIT to Interest (avg)
27.14
Debt to EBITDA (avg)
0.71
Net Debt to Equity (avg)
-0.04
Sales to Capital Employed (avg)
0.76
Tax Ratio
19.69%
Dividend Payout Ratio
10.17%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.52%
ROE (avg)
16.02%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
0.95
EV to EBIT
7.60
EV to EBITDA
4.83
EV to Capital Employed
0.95
EV to Sales
0.94
PEG Ratio
0.05
Dividend Yield
0.64%
ROCE (Latest)
12.44%
ROE (Latest)
11.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
920.30
917.70
0.28%
Operating Profit (PBDIT) excl Other Income
169.90
190.00
-10.58%
Interest
2.20
3.00
-26.67%
Exceptional Items
-0.30
-0.10
-200.00%
Consolidate Net Profit
151.50
116.70
29.82%
Operating Profit Margin (Excl OI)
184.60%
139.70%
4.49%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 0.28% vs 20.96% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 29.82% vs 34.60% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,323.90
2,737.40
21.43%
Operating Profit (PBDIT) excl Other Income
665.80
409.90
62.43%
Interest
26.60
33.20
-19.88%
Exceptional Items
-28.00
53.40
-152.43%
Consolidate Net Profit
368.80
104.20
253.93%
Operating Profit Margin (Excl OI)
130.40%
65.80%
6.46%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 21.43% vs -34.57% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 253.93% vs -74.25% in Dec 2023
About Allmed Medical Products Co., Ltd. 
Allmed Medical Products Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






